Funding for this research was provided by:
National Cancer Institute (U54 CA217377, P30-CA14051)
National Institutes of Health (1DP2OD020839, 2RM1HG006193, 1R33CA202820, 2U19AI089992, 1R01HL134539, 2P01AI039671, R33CA191143, 5U24AI118672)
Alfred P. Sloan Foundation (NA)
Pew Charitable Trusts (Pew-Stewart Scholar)
Received: 3 April 2018
Accepted: 31 October 2018
First Online: 27 November 2018
Ethics approval and consent to participate
: The GBM PDCL BT159 was generated using patient tissue collected under a protocol (Dana Farber Harvard Cancer Center protocol #10-043) approved by Dana Farber Harvard Cancer Center and Partner’s Human Research Center institutional review boards. All experiments comply with the Declaration of Helsinki. Animals were cared for in accordance with federal, state and local guidelines following a protocol approved by the Department of Comparative Medicine at MIT (protocol number 0317-022-20).
: Not applicable.
: RJK, MMS, SO, KLL, and SRM declare competing financial interests as cofounders of Travera, which develops technology relevant to the research presented. SRM declares competing financial interests as a cofounder of Affinity Biosensors, which develops technology relevant to the research presented. KLL declares competing financial interests as a consultant for Bristol-Myers Squibb in a capacity relevant to the research presented.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.